# The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually

> **NIH NIH R13** · IAS · 2022 · $885,000

## Abstract

Project Summary
The advances in HIV science across the past 40 years have been remarkable, with near normal life expectancy
for persons on antiviral therapy and ever widening access to prevention, treatment and care. However, we do
not have an effective HIV vaccine or a cure for the 37 million people living with HIV infection worldwide. The
June 2021 United Nations Political Declaration on HIV and AIDS sets new targets and offers welcome clarity on
the breadth of policy interventions and resource investments required to meet these objectives. But these will
only become a reality if evidence informs policy and scientific innovation continues to provide ever better
solutions to remaining biomedical, socio-behavioral and implementation challenges. A global convening bringing
together scientists, clinicians, affected community leadership, implementers, donors, and political leaders is thus
urgently needed to critically define future research agendas, shift new evidence to action and chart a new
consensus on achieving the still elusive goal of pandemic control of HIV. The theme of AIDS 2022, “Re-engage
& follow the science” epitomizes this urgency.
Recognizing that uneven rollout of COVID-19 vaccines will likely prevent many key stakeholders particularly from
countries with a high burden of HIV from travelling internationally, AIDS 2022 will be a fully hybrid conference
(29 July-2 August 2022). In addition to the virtual conference platform, Montreal will provide a compelling venue
for AIDS 2022 as a leading center of HIV science, with a view to the progressive Canadian policy environment
for those at risk and in recognition of Canadian leadership in global cooperation to address the epidemic.
Specific aims for AIDS 2022 are to:
1. Accelerate scientific discovery to drive innovation across the HIV prevention and treatment cascades,
 including pathogenesis, transmission, vaccines, remission and a functional cure; long-acting oral and
 injectable treatment and prevention technologies, including rings for prevention; integrated and differentiated
 models of care; and analyses of structural and economic determinants of health.
2. Accelerate updates to treatment guidance especially for low and middle-income countries, infected
 children and persons with HIV, TB, viral hepatitis and COVID-19 infection.
3. Facilitate the adaptation of innovations from the response to COVID-19 across science, policy and
 practice and consolidating good practice for pandemic preparedness, and immunization efforts including new
 partnerships between public and private stakeholders and learnings from adaptations from the HIV response
 that accelerated the response to COVID-19.
4. Advance core components of implementation science research that address the challenges and
 opportunities of integration across a range of epidemic settings and in the COVID-19 era, including findings
 from community-led research, monitoring and innovations in service delivery, including telemedicine.
5...

## Key facts

- **NIH application ID:** 10481133
- **Project number:** 1R13AI170179-01
- **Recipient organization:** IAS
- **Principal Investigator:** Christopher C. Beyrer
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $885,000
- **Award type:** 1
- **Project period:** 2022-04-19 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10481133

## Citation

> US National Institutes of Health, RePORTER application 10481133, The 24th International AIDS Conference (AIDS 2022), 29 July-2 August 2022, Montreal, Canada and virtually (1R13AI170179-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10481133. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*